Verified factor-similar pair

MDYG vs SCHM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
88
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SCHM has the higher backtested relative Sharpe (0.918 vs 0.890).
  • SCHM has the lower published fee (0.04% vs 0.15%).
  • SCHM is cheaper on dividend valuation (116 vs 170, where 100 is each fund's historical median).
  • SCHM has the stronger regression fit (adjusted R-squared 0.947 vs 0.909).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

MDYG

State Street SPDR S&P 400 Mid Cap Growth ETF
SMB
Adj. R2
0.909
Rel. Sharpe
0.890
Mkt beta
1.03
AUM
US$2.6B
MER
0.15%
Valuation
170

SCHM

Schwab U.S. Mid-Cap ETF
SMB
Adj. R2
0.947
Rel. Sharpe
0.918
Mkt beta
1.02
AUM
US$13.6B
MER
0.04%
Valuation
116

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
MDYG
+0.46
|t|
+10.4
SCHM
+0.42
|t|
+10.8
diff +0.05
HML
MDYG
-0.07
|t|
-1.7
SCHM
+0.13
|t|
+3.5
diff -0.20
RMW
MDYG
+0.11
|t|
+2.0
SCHM
+0.03
|t|
+0.7
diff +0.08
CMA
MDYG
+0.01
|t|
+0.1
SCHM
-0.01
|t|
-0.2
diff +0.01
UMD
MDYG
+0.03
|t|
+1.0
SCHM
+0.03
|t|
+1.2
diff -0.00

Why This Pair Matches

Exposure level
86
Exposure shape
94
Mkt beta diff
0.00
Rel. Sharpe diff
0.028

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

MDYG fund page SCHM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.